vs

Side-by-side financial comparison of Kinetik Holdings Inc. (KNTK) and Revvity (RVTY). Click either name above to swap in a different company.

Revvity is the larger business by last-quarter revenue ($772.1M vs $430.4M, roughly 1.8× Kinetik Holdings Inc.). Kinetik Holdings Inc. runs the higher net margin — 96.8% vs 12.7%, a 84.1% gap on every dollar of revenue. On growth, Kinetik Holdings Inc. posted the faster year-over-year revenue change (11.6% vs 5.9%). Revvity produced more free cash flow last quarter ($161.8M vs $-24.0M). Over the past eight quarters, Kinetik Holdings Inc.'s revenue compounded faster (12.3% CAGR vs 9.0%).

Kinetik Holdings Inc. is a midstream energy infrastructure provider primarily focused on the Permian Basin region. It delivers integrated solutions including natural gas gathering, processing, transportation and storage, as well as crude oil and produced water handling services for upstream oil and gas operators across major energy production areas in the southern United States.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

KNTK vs RVTY — Head-to-Head

Bigger by revenue
RVTY
RVTY
1.8× larger
RVTY
$772.1M
$430.4M
KNTK
Growing faster (revenue YoY)
KNTK
KNTK
+5.7% gap
KNTK
11.6%
5.9%
RVTY
Higher net margin
KNTK
KNTK
84.1% more per $
KNTK
96.8%
12.7%
RVTY
More free cash flow
RVTY
RVTY
$185.8M more FCF
RVTY
$161.8M
$-24.0M
KNTK
Faster 2-yr revenue CAGR
KNTK
KNTK
Annualised
KNTK
12.3%
9.0%
RVTY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KNTK
KNTK
RVTY
RVTY
Revenue
$430.4M
$772.1M
Net Profit
$416.7M
$98.4M
Gross Margin
Operating Margin
11.2%
14.5%
Net Margin
96.8%
12.7%
Revenue YoY
11.6%
5.9%
Net Profit YoY
2468.4%
3.9%
EPS (diluted)
$2.22
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KNTK
KNTK
RVTY
RVTY
Q4 25
$430.4M
$772.1M
Q3 25
$464.0M
$698.9M
Q2 25
$426.7M
$720.3M
Q1 25
$443.3M
$664.8M
Q4 24
$385.7M
$729.4M
Q3 24
$396.4M
$684.0M
Q2 24
$359.5M
$691.7M
Q1 24
$341.4M
$649.9M
Net Profit
KNTK
KNTK
RVTY
RVTY
Q4 25
$416.7M
$98.4M
Q3 25
$5.3M
$46.7M
Q2 25
$23.6M
$53.9M
Q1 25
$19.3M
$42.2M
Q4 24
$16.2M
$94.6M
Q3 24
$25.8M
$94.4M
Q2 24
$37.2M
$55.4M
Q1 24
$233.6M
$26.0M
Gross Margin
KNTK
KNTK
RVTY
RVTY
Q4 25
Q3 25
53.6%
Q2 25
54.5%
Q1 25
56.5%
Q4 24
Q3 24
56.3%
Q2 24
55.7%
Q1 24
54.6%
Operating Margin
KNTK
KNTK
RVTY
RVTY
Q4 25
11.2%
14.5%
Q3 25
4.3%
11.7%
Q2 25
18.2%
12.6%
Q1 25
4.3%
10.9%
Q4 24
6.1%
16.3%
Q3 24
18.4%
14.3%
Q2 24
15.7%
12.4%
Q1 24
7.6%
6.8%
Net Margin
KNTK
KNTK
RVTY
RVTY
Q4 25
96.8%
12.7%
Q3 25
1.1%
6.7%
Q2 25
5.5%
7.5%
Q1 25
4.3%
6.4%
Q4 24
4.2%
13.0%
Q3 24
6.5%
13.8%
Q2 24
10.3%
8.0%
Q1 24
68.4%
4.0%
EPS (diluted)
KNTK
KNTK
RVTY
RVTY
Q4 25
$2.22
$0.86
Q3 25
$0.03
$0.40
Q2 25
$0.33
$0.46
Q1 25
$0.05
$0.35
Q4 24
$0.01
$0.77
Q3 24
$0.35
$0.77
Q2 24
$0.54
$0.45
Q1 24
$0.12
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KNTK
KNTK
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$4.0M
$919.9M
Total DebtLower is stronger
$3.6B
Stockholders' EquityBook value
$-565.4M
$7.3B
Total Assets
$7.1B
$12.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KNTK
KNTK
RVTY
RVTY
Q4 25
$4.0M
$919.9M
Q3 25
$7.7M
$931.4M
Q2 25
$10.7M
$991.8M
Q1 25
$8.8M
$1.1B
Q4 24
$3.6M
$1.2B
Q3 24
$20.4M
$1.2B
Q2 24
$12.5M
$2.0B
Q1 24
$9.8M
$1.7B
Total Debt
KNTK
KNTK
RVTY
RVTY
Q4 25
$3.6B
Q3 25
$4.0B
Q2 25
$3.7B
Q1 25
$3.6B
Q4 24
$3.4B
Q3 24
$3.3B
Q2 24
$3.3B
Q1 24
$3.5B
Stockholders' Equity
KNTK
KNTK
RVTY
RVTY
Q4 25
$-565.4M
$7.3B
Q3 25
$-1.8B
$7.4B
Q2 25
$-1.6B
$7.6B
Q1 25
$-2.5B
$7.6B
Q4 24
$-3.0B
$7.7B
Q3 24
$-1.7B
$7.9B
Q2 24
$-1.2B
$7.9B
Q1 24
$-973.4M
$7.8B
Total Assets
KNTK
KNTK
RVTY
RVTY
Q4 25
$7.1B
$12.2B
Q3 25
$7.2B
$12.1B
Q2 25
$7.2B
$12.4B
Q1 25
$7.0B
$12.4B
Q4 24
$6.8B
$12.4B
Q3 24
$6.9B
$12.8B
Q2 24
$6.9B
$13.4B
Q1 24
$6.4B
$13.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KNTK
KNTK
RVTY
RVTY
Operating Cash FlowLast quarter
$110.1M
$182.0M
Free Cash FlowOCF − Capex
$-24.0M
$161.8M
FCF MarginFCF / Revenue
-5.6%
21.0%
Capex IntensityCapex / Revenue
31.2%
2.6%
Cash ConversionOCF / Net Profit
0.26×
1.85×
TTM Free Cash FlowTrailing 4 quarters
$111.6M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KNTK
KNTK
RVTY
RVTY
Q4 25
$110.1M
$182.0M
Q3 25
$188.1M
$138.5M
Q2 25
$129.1M
$134.3M
Q1 25
$176.8M
$128.2M
Q4 24
$144.0M
$174.2M
Q3 24
$214.1M
$147.9M
Q2 24
$125.5M
$158.6M
Q1 24
$153.7M
$147.6M
Free Cash Flow
KNTK
KNTK
RVTY
RVTY
Q4 25
$-24.0M
$161.8M
Q3 25
$31.6M
$120.0M
Q2 25
$1.8M
$115.5M
Q1 25
$102.3M
$112.2M
Q4 24
$36.3M
$149.8M
Q3 24
$155.7M
$125.6M
Q2 24
$86.1M
$136.6M
Q1 24
$95.7M
$129.7M
FCF Margin
KNTK
KNTK
RVTY
RVTY
Q4 25
-5.6%
21.0%
Q3 25
6.8%
17.2%
Q2 25
0.4%
16.0%
Q1 25
23.1%
16.9%
Q4 24
9.4%
20.5%
Q3 24
39.3%
18.4%
Q2 24
24.0%
19.7%
Q1 24
28.0%
20.0%
Capex Intensity
KNTK
KNTK
RVTY
RVTY
Q4 25
31.2%
2.6%
Q3 25
33.7%
2.6%
Q2 25
29.8%
2.6%
Q1 25
16.8%
2.4%
Q4 24
27.9%
3.4%
Q3 24
14.7%
3.3%
Q2 24
11.0%
3.2%
Q1 24
17.0%
2.7%
Cash Conversion
KNTK
KNTK
RVTY
RVTY
Q4 25
0.26×
1.85×
Q3 25
35.73×
2.97×
Q2 25
5.46×
2.49×
Q1 25
9.18×
3.03×
Q4 24
8.88×
1.84×
Q3 24
8.31×
1.57×
Q2 24
3.37×
2.87×
Q1 24
0.66×
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KNTK
KNTK

Natural Gas NG Ls And Condensate Sales$325.5M76%
Gathering And Processing Services$101.6M24%
Other$3.3M1%
Barilla Draw$2.3M1%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons